Modality
Cell Therapy
MOA
JAK1i
Target
PSMA
Pathway
Incretin
MMAMLIPF
Development Pipeline
Preclinical
~Mar 2016
→ ~Jun 2017
Phase 1
~Sep 2017
→ ~Dec 2018
Phase 2
~Mar 2019
→ ~Jun 2020
Phase 3
~Sep 2020
→ ~Dec 2021
NDA/BLA
Mar 2022
→ Dec 2028
NDA/BLACurrent
NCT03303203
1,193 pts·MM
2022-03→2028-12·Recruiting
NCT07969733
155 pts·MM
2024-07→TBD·Terminated
1,348 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-12-202.7y awayPh3 Readout· MM
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
NDA/BLA
Recruit…
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2028-12-20 · 2.7y away
MM
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03303203 | NDA/BLA | MM | Recruiting | 1193 | Safety |
| NCT07969733 | NDA/BLA | MM | Terminated | 155 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Doxacagene | Sanofi | Approved | PSMA | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| ARG-1924 | Argenx | Preclinical | DLL3 |